Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

– End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA –

– Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 –